産後うつ病治療薬の市場規模、シェア、動向分析レポート：タイプ別、治療別、投与経路別、流通チャネル別、地域別、セグメント別予測、2024年～2030年

産後うつ病治療薬市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の産後うつ病治療薬市場は2030年までに15億9,000万米ドルに達すると予測され、予測期間中にCAGR 9.63％で拡大する見込みです。

世界の妊娠数の増加が主に市場成長の原動力となっています。多くの女性が出産後に産後うつ病（PPD）に罹患し、後に大うつ病を発症するリスクが高いです。クリーブランド・クリニックの概算によると、産後うつ病は出産後の女性の7人に1人が罹患する一般的な疾患です。したがって、出産を経験し、PDDのような気分障害に苦しむ女性に対する政府支援の高まりが、予測期間中の医薬品需要を押し上げると予想されます。

Indian Association of Preventive &Social Medicineによると、毎年約3,000万人の女性が妊娠を経験し、2,700万人の女性が出産を経験しています。2022年7月、インド政府はJanani Suraksha Yojana（JSY）やJanani Shishu Suraksha Karyakaram（JSSK）など、妊婦を支援する複数の制度を開始しました。これらのプログラムでは、政府は診断、医薬品、その他の消耗品など、妊娠に関する治療を無料で提供しています。したがって、JSSKやJSYのようなイニシアチブは、女性が産後うつ病などの治療を完了するのを支援し、同時に予測期間中の市場成長を促進します。

産後うつ病治療薬の採用を促進するもう一つの重要な要因は、ヘルスケア支出の増加であり、これはインフラを改善し、医療施設への患者のアクセスを向上させるのに役立っています。PETERSON-KFF Health System Trackerレポートによると、女性は妊娠、出産、産後の治療に年間約1万8,865米ドルを費やしています。これには大きなばらつきがあり、支出や費用は世界の地域によって大きく異なります。女性のPPD治療へのアクセスの増加は、今後数年間の市場成長を促進すると予想されます。

産後うつ病治療薬市場レポートハイライト

• 2023年には、産後不安分野が市場の最大シェアを占めました。これは、同疾患の治療率の高さ、先進国および新興諸国における有病率の高まりに起因しています。
• 治療タイプに基づくと、ホルモン療法セグメントは予測期間中に最も速いCAGRで成長すると予想されます。これは、新しいホルモン剤の開発と商業化、およびPDD治療のための小規模病院や施設による採用の増加に起因することができます。
• 2023年、投与経路に基づく市場では経口剤が最大のシェアを占めました。この優位性は、世界の疾患の有病率と発生率の増加、製品の豊富な入手可能性、治療のための新しい経口ジェネリック医薬品に対する需要の高まりに起因しています。
• 病院薬局セグメントは、2023年に流通チャネルに基づく市場で最大のシェアを占めました。病院での治療率、PDD治療において患者が他の医療環境よりも病院を好むこと、病院を訪れる患者数が増加していることなどが背景にあります。
• 北米は、先進的なヘルスケアインフラ、疾患有病率の上昇、良好な規制環境などの要因により、市場を独占しました。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 産後うつ病治療薬市場の変数、動向、範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場牽引要因分析
  • 市場抑制要因分析
• 産後うつ病治療薬市場分析ツール
  • 業界分析- ポーターのファイブフォース分析
  • PESTEL分析
  • パイプライン分析

第4章 産後うつ病治療薬市場：タイプ別推定・動向分析

• 世界の産後うつ病治療薬市場：タイプダッシュボード
• 世界の産後うつ病治療薬市場：タイプ変動分析
• 産後うつ病治療薬の世界市場：治療、収益別
• 産後ブルース
• 産後不安
• 産後強迫性障害（OCD）
• 産後心的外傷後ストレス障害（PTSD）
• 産後パニック障害
• 予防

第5章 産後うつ病治療薬市場：治療別推定・動向分析

• 世界の産後うつ病治療薬市場：治療ダッシュボード
• 世界の産後うつ病治療薬市場：治療変動分析
• 治療別、収益
• 薬物療法
• ホルモン療法
• その他

第6章 産後うつ病治療薬市場：投与経路別推定・動向分析

• 世界の産後うつ病治療薬市場：投与経路ダッシュボード
• 世界の産後うつ病治療薬市場：投与経路の変動分析
• 投与経路別、収益
• 非経口
• 経口
• その他

第7章 産後うつ病治療薬市場：流通チャネル別推定・動向分析

• 世界の産後うつ病治療薬市場：流通チャネルダッシュボード
• 世界の産後うつ病治療薬市場：流通チャネル変動分析
• 流通チャネル別、収益
• 病院薬局
• 小売薬局
• その他（オンライン薬局）

第8章 産後うつ病治療薬市場：治療、治療クラス、投与経路別の地域推定・動向分析

• 地域ダッシュボード
• 市場規模、予測動向分析、2018年から2030年：
• 北米
• 欧州
• アジア太平洋地域
• ラテンアメリカ
• 中東・アフリカ

第9章 競合情勢

• 企業/競合の分類
• ベンダー情勢
  • 主要ディストリビューターおよびチャネルパートナーのリスト
  • 主要顧客
  • 主要企業の市場シェア分析、2023年
  • Sage Therapeutics, Inc.
  • Pfizer Inc.
  • Eli Lilly and Company.
  • GSK plc
  • Merck &Co., Inc.
  • Biogen Inc.
  • Bausch Health Companies Inc.
  • Cipla Inc.
  • Novartis AG.
  • Teva Pharmaceutical Industries Ltd.

List of Tables

• Table 1 List of abbreviation
• Table 2 North America postpartum depression drugs market, by region, 2018 - 2030 (USD Million)
• Table 3 North America postpartum depression drugs market, by type, 2018 - 2030 (USD Million)
• Table 4 North America postpartum depression drugs market, by treatment, 2018 - 2030 (USD Million)
• Table 5 North America postpartum depression drugs market, by route of administration, 2018 - 2030 (USD Million)
• Table 6 North America postpartum depression drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 7 U.S. postpartum depression drugs market, by type, 2018 - 2030 (USD Million)
• Table 8 U.S. postpartum depression drugs market, by treatment, 2018 - 2030 (USD Million)
• Table 9 U.S. postpartum depression drugs market, by route of administration, 2018 - 2030 (USD Million)
• Table 10 U.S. postpartum depression drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 11 Canada postpartum depression drugs market, by type, 2018 - 2030 (USD Million)
• Table 12 Canada postpartum depression drugs market, by treatment, 2018 - 2030 (USD Million)
• Table 13 Canada postpartum depression drugs market, by route of administration, 2018 - 2030 (USD Million)
• Table 14 Canada postpartum depression drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 15 Mexico postpartum depression drugs market, by type, 2018 - 2030 (USD Million)
• Table 16 Mexico postpartum depression drugs market, by treatment, 2018 - 2030 (USD Million)
• Table 17 Mexico postpartum depression drugs market, by route of administration, 2018 - 2030 (USD Million)
• Table 18 Mexico postpartum depression drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 19 Europe postpartum depression drugs market, by region, 2018 - 2030 (USD Million)
• Table 20 Europe postpartum depression drugs market, by type, 2018 - 2030 (USD Million)
• Table 21 Europe postpartum depression drugs market, by treatment, 2018 - 2030 (USD Million)
• Table 22 Europe postpartum depression drugs market, by route of administration, 2018 - 2030 (USD Million)
• Table 23 Europe postpartum depression drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 24 Germany postpartum depression drugs market, by type, 2018 - 2030 (USD Million)
• Table 25 Germany postpartum depression drugs market, by treatment, 2018 - 2030 (USD Million)
• Table 26 Germany postpartum depression drugs market, by route of administration, 2018 - 2030 (USD Million)
• Table 27 Germany postpartum depression drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 28 UK postpartum depression drugs market, by type, 2018 - 2030 (USD Million)
• Table 29 UK postpartum depression drugs market, by treatment, 2018 - 2030 (USD Million)
• Table 30 UK postpartum depression drugs market, by route of administration, 2018 - 2030 (USD Million)
• Table 31 UK postpartum depression drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 32 France postpartum depression drugs market, by type, 2018 - 2030 (USD Million)
• Table 33 France postpartum depression drugs market, by treatment, 2018 - 2030 (USD Million)
• Table 34 France postpartum depression drugs market, by route of administration, 2018 - 2030 (USD Million)
• Table 35 France postpartum depression drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 36 Italy postpartum depression drugs market, by type, 2018 - 2030 (USD Million)
• Table 37 Italy postpartum depression drugs market, by treatment, 2018 - 2030 (USD Million)
• Table 38 Italy postpartum depression drugs market, by route of administration, 2018 - 2030 (USD Million)
• Table 39 Italy postpartum depression drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 40 Spain postpartum depression drugs market, by type, 2018 - 2030 (USD Million)
• Table 41 Spain postpartum depression drugs market, by treatment, 2018 - 2030 (USD Million)
• Table 42 Spain postpartum depression drugs market, by route of administration, 2018 - 2030 (USD Million)
• Table 43 Spain postpartum depression drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 44 Denmark postpartum depression drugs market, by type, 2018 - 2030 (USD Million)
• Table 45 Denmark postpartum depression drugs market, by treatment, 2018 - 2030 (USD Million)
• Table 46 Denmark postpartum depression drugs market, by route of administration, 2018 - 2030 (USD Million)
• Table 47 Denmark postpartum depression drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 48 Sweden postpartum depression drugs market, by type, 2018 - 2030 (USD Million)
• Table 49 Sweden postpartum depression drugs market, by treatment, 2018 - 2030 (USD Million)
• Table 50 Sweden postpartum depression drugs market, by route of administration, 2018 - 2030 (USD Million)
• Table 51 Sweden postpartum depression drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 52 Norway postpartum depression drugs market, by type, 2018 - 2030 (USD Million)
• Table 53 Norway postpartum depression drugs market, by treatment, 2018 - 2030 (USD Million)
• Table 54 Norway postpartum depression drugs market, by route of administration, 2018 - 2030 (USD Million)
• Table 55 Norway postpartum depression drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 56 Asia Pacific postpartum depression drugs market, by region, 2018 - 2030 (USD Million)
• Table 57 Asia Pacific postpartum depression drugs market, by type, 2018 - 2030 (USD Million)
• Table 58 Asia Pacific postpartum depression drugs market, by treatment, 2018 - 2030 (USD Million)
• Table 59 Aisa Pacific postpartum depression drugs market, by route of administration, 2018 - 2030 (USD Million)
• Table 60 Asia Pacific postpartum depression drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 61 China postpartum depression drugs market, by type, 2018 - 2030 (USD Million)
• Table 62 China postpartum depression drugs market, by treatment, 2018 - 2030 (USD Million)
• Table 63 China postpartum depression drugs market, by route of administration, 2018 - 2030 (USD Million)
• Table 64 China postpartum depression drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 65 Japan postpartum depression drugs market, by type, 2018 - 2030 (USD Million)
• Table 66 Japan postpartum depression drugs market, by treatment, 2018 - 2030 (USD Million)
• Table 67 Japan postpartum depression drugs market, by route of administration, 2018 - 2030 (USD Million)
• Table 68 Japan postpartum depression drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 69 India postpartum depression drugs market, by type, 2018 - 2030 (USD Million)
• Table 70 India postpartum depression drugs market, by treatment, 2018 - 2030 (USD Million)
• Table 71 India postpartum depression drugs market, by route of administration, 2018 - 2030 (USD Million)
• Table 72 India postpartum depression drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 73 South Korea postpartum depression drugs market, by type, 2018 - 2030 (USD Million)
• Table 74 South Korea postpartum depression drugs market, by treatment, 2018 - 2030 (USD Million)
• Table 75 South Korea postpartum depression drugs market, by route of administration, 2018 - 2030 (USD Million)
• Table 76 South Korea postpartum depression drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 77 Australia postpartum depression drugs market, by type, 2018 - 2030 (USD Million)
• Table 78 Australia postpartum depression drugs market, by treatment, 2018 - 2030 (USD Million)
• Table 79 Australia postpartum depression drugs market, by route of administration, 2018 - 2030 (USD Million)
• Table 80 Australia postpartum depression drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 81 Thailand postpartum depression drugs market, by type, 2018 - 2030 (USD Million)
• Table 82 Thailand postpartum depression drugs market, by treatment, 2018 - 2030 (USD Million)
• Table 83 Thailand postpartum depression drugs market, by route of administration, 2018 - 2030 (USD Million)
• Table 84 Thailand postpartum depression drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 85 Latin America postpartum depression drugs market, by region, 2018 - 2030 (USD Million)
• Table 86 Latin America postpartum depression drugs market, by type, 2018 - 2030 (USD Million)
• Table 87 Latin America postpartum depression drugs market, by treatment, 2018 - 2030 (USD Million)
• Table 88 Latin America postpartum depression drugs market, by route of administration, 2018 - 2030 (USD Million)
• Table 89 Latin America postpartum depression drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 90 Brazil postpartum depression drugs market, by type, 2018 - 2030 (USD Million)
• Table 91 Brazil postpartum depression drugs market, by treatment, 2018 - 2030 (USD Million)
• Table 92 Brazil postpartum depression drugs market, by route of administration, 2018 - 2030 (USD Million)
• Table 93 Brazil postpartum depression drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 94 Argentina postpartum depression drugs market, by type, 2018 - 2030 (USD Million)
• Table 95 Argentina postpartum depression drugs market, by treatment, 2018 - 2030 (USD Million)
• Table 96 Argentina postpartum depression drugs market, by route of administration, 2018 - 2030 (USD Million)
• Table 97 Argentina postpartum depression drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 98 MEA postpartum depression drugs market, by region, 2018 - 2030 (USD Million)
• Table 99 MEA postpartum depression drugs market, by type, 2018 - 2030 (USD Million)
• Table 100 MEA postpartum depression drugs market, by treatment, 2018 - 2030 (USD Million)
• Table 101 MEA postpartum depression drugs market, by route of administration, 2018 - 2030 (USD Million)
• Table 102 MEA postpartum depression drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 103 South Africa postpartum depression drugs market, by type, 2018 - 2030 (USD Million)
• Table 104 South Africa postpartum depression drugs market, by treatment, 2018 - 2030 (USD Million)
• Table 105 South Africa postpartum depression drugs market, by route of administration, 2018 - 2030 (USD Million)
• Table 106 South Africa postpartum depression drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 107 Saudi Arabia postpartum depression drugs market, by type, 2018 - 2030 (USD Million)
• Table 108 Saudi Arabia postpartum depression drugs market, by treatment, 2018 - 2030 (USD Million)
• Table 109 Saudi Arabia postpartum depression drugs market, by route of administration, 2018 - 2030 (USD Million)
• Table 110 Saudi Arabia postpartum depression drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 111 UAE postpartum depression drugs market, by type, 2018 - 2030 (USD Million)
• Table 112 UAE postpartum depression drugs market, by treatment, 2018 - 2030 (USD Million)
• Table 113 UAE postpartum depression drugs market, by route of administration, 2018 - 2030 (USD Million)
• Table 114 UAE postpartum depression drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 115 Kuwait postpartum depression drugs market, by type, 2018 - 2030 (USD Million)
• Table 116 Kuwait postpartum depression drugs market, by treatment, 2018 - 2030 (USD Million)
• Table 117 Kuwait postpartum depression drugs market, by route of administration, 2018 - 2030 (USD Million)
• Table 118 Kuwait postpartum depression drugs market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Primary interviews in North America
• Fig. 5 Primary interviews in Europe
• Fig. 6 Primary interviews in APAC
• Fig. 7 Primary interviews in Latin America
• Fig. 8 Primary interviews in MEA
• Fig. 9 Market research approaches
• Fig. 10 Value-chain-based sizing & forecasting
• Fig. 11 QFD modeling for market share assessment
• Fig. 12 Market formulation & validation
• Fig. 13 Postpartum depression drugs market: market outlook
• Fig. 14 Postpartum depression drugs competitive insights
• Fig. 15 Parent market outlook
• Fig. 16 Related/ancillary market outlook
• Fig. 17 Postpartum depression drugs market driver impact
• Fig. 18 Postpartum depression drugs market restraint impact
• Fig. 19 Postpartum depression drugs market: Type movement analysis
• Fig. 20 Postpartum depression drugs market: Type outlook and key takeaways
• Fig. 21 Postpartum blues market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 22 Postpartum anxiety market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 23 Postpartum obsessive-compulsive disorder (OCD) market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 24 Postpartum post-traumatic stress disorder (PTSD) market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 25 Postpartum panic disorder market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 26 Postpartum psychosis market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 27 Postpartum depression drugs market: Treatment movement analysis
• Fig. 28 Postpartum depression drugs market: Treatment outlook and key takeaways
• Fig. 29 Pharmacotherapy market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 30 Hormonal therapy market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 31 Others market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 32 Postpartum depression drugs market: Route of administration movement analysis
• Fig. 33 Postpartum depression drugs market: Route of administration outlook and key takeaways
• Fig. 34 Parenteral market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 35 Oral market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 36 Others market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 37 Postpartum depression drugs market: Distribution Channel movement analysis
• Fig. 38 Postpartum depression drugs market: Distribution Channel outlook and key takeaways
• Fig. 39 Hospital pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 40 Retail pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 41 Others (online pharmacy) market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 42 Global Postpartum Depression Drugs market: Regional movement analysis
• Fig. 43 Global Postpartum Depression Drugs market: Regional outlook and key takeaways
• Fig. 44 Global Postpartum Depression Drugs market share and leading players
• Fig. 45 North America, by country
• Fig. 46 North America market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 47 U.S. key country dynamics
• Fig. 48 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 49 Canada key country dynamics
• Fig. 50 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 51 Mexico key country dynamics
• Fig. 52 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 53 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 54 UK key country dynamics
• Fig. 55 UK market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 56 Germany key country dynamics
• Fig. 57 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 58 France key country dynamics
• Fig. 59 France market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 60 Italy key country dynamics
• Fig. 61 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 62 Spain key country dynamics
• Fig. 63 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 64 Denmark key country dynamics
• Fig. 65 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 66 Sweden key country dynamics
• Fig. 67 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 68 Norway key country dynamics
• Fig. 69 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 70 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 71 China key country dynamics
• Fig. 72 China market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 73 Japan key country dynamics
• Fig. 74 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 75 India key country dynamics
• Fig. 76 India market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 77 Thailand key country dynamics
• Fig. 78 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 79 South Korea key country dynamics
• Fig. 80 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 81 Australia key country dynamics
• Fig. 82 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 83 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 84 Brazil key country dynamics
• Fig. 85 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 86 Argentina key country dynamics
• Fig. 87 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 88 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 89 South Africa key country dynamics
• Fig. 90 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 91 Saudi Arabia key country dynamics
• Fig. 92 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 93 UAE key country dynamics
• Fig. 94 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 95 Kuwait key country dynamics
• Fig. 96 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 97 Market share of key market players- postpartum depression drugs market

Postpartum Depression Drugs Market Growth & Trends:

The global postpartum depression drugs market is anticipated to reach USD 1.59 billion by 2030 and is expected to expand at a CAGR of 9.63% during the forecast period, according to a new report by Grand View Research, Inc. The increasing number of pregnancies worldwide primarily drives market growth. Many women suffer from postpartum depression (PPD) after having a baby and are at high risk of developing major depression later in life. According to the Cleveland Clinic Estimate, postpartum depression is a common condition that affects 1 in 7 women after giving birth to a child. Thus, rising government support for women who had childbirth and are suffering from mood disorders like PDD is expected to boost demand for drugs over the forecast period.

According to the Indian Association of Preventive & Social Medicine, every year, around 30 million women experience pregnancy, and 27 million women have live childbirths. In July 2022, the Government of India launched several schemes to support pregnant women, such as Janani Suraksha Yojana (JSY) and Janani Shishu Suraksha Karyakaram (JSSK). Under these programs, the government offers free of cost treatment related to pregnancy, such as diagnostics, medicines, and other consumables. Thus, initiatives like JSSK and JSY support women in completing treatment such as postpartum depression, simultaneously driving market growth during the forecast period.

Another significant factor driving the adoption of postpartum depression drugs is rising healthcare expenditures, which help to improve infrastructure and improve patient access to healthcare facilities. According to the PETERSON-KFF Health System Tracker report, women spend around USD 18,865 annually on pregnancy, childbirth, and postpartum treatment. There is significant variation. around this, spending and costs vary significantly by region worldwide. The increasing access of women to PPD drug treatment is anticipated to drive market growth in the coming years.

Postpartum Depression Drugs Market Report Highlights:

• The postpartum anxiety segment held the largest share of the market in 2023. This can be attributed to the disease's high treatment rate and growing prevalence in developed and developing countries.
• Based on the treatment type, the hormonal therapy segment is expected to grow at the fastest CAGR during the forecast period.This can be attributed to the development and commercialization of new hormonal drugs and increased adoption by smaller hospitals and facilities for the treatment of PDD.
• In 2023, the oral segment held the largest share of the market based on the route of administration. This dominance can be attributed to the increase in the prevalence and incidence of disease worldwide, the large availability of products, and the rising demand for new generic oral drugs for treatment.
• The hospital pharmacy segment held the largest share of the market based on distribution channels in 2023. Hospital treatment rates, patient preference for hospitals over other healthcare settings for PDD treatment, and the increasing number of patients visiting hospitals.
• North America dominated the market owing to factors such as advanced healthcare infrastructure, rising disease prevalence, and favorable regulatory environment.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Treatment
  • 1.2.3. Route of Administration
  • 1.2.4. Distribution Channel
  • 1.2.5. Regional scope
  • 1.2.6. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Treatment and Treatment outlook
  • 2.2.2. Route of Administration outlook
  • 2.2.3. Distribution Channel and Availability outlook
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Postpartum Depression Drugs Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing prevalence of postpartum depression
    • 3.2.1.2. Advancements in drug development
    • 3.2.1.3. Growing awareness and diagnosis
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High cost of treatment
    • 3.2.2.2. Regulatory challenges for new drug approvals
• 3.3. Postpartum Depression Drugs Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's Five Forces
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
  • 3.3.3. Pipeline Analysis

Chapter 4. Postpartum Depression Drugs Market: Treatment Estimates & Trend Analysis

• 4.1. Global Postpartum Depression Drugs Market: Type Dashboard
• 4.2. Global Postpartum Depression Drugs Market: Type Movement Analysis
• 4.3. Global Postpartum Depression Drugs Market by Treatment, Revenue
• 4.4. Postpartum Blues
  • 4.4.1. Postpartum blues market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Postpartum Anxiety
  • 4.5.1. Postpartum anxiety market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Postpartum Obsessive-Compulsive Disorder (OCD)
  • 4.6.1. Postpartum obsessive-compulsive disorder (OCD) market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Postpartum Post-Traumatic Stress Disorder (PTSD)
  • 4.7.1. Postpartum post-traumatic stress disorder (PTSD) market estimates and forecasts 2018 to 2030 (USD Million)
• 4.8. Postpartum Panic Disorder
  • 4.8.1. Postpartum panic disorder market estimates and forecasts 2018 to 2030 (USD Million)
• 4.9. Preventive
  • 4.9.1. Postpartum psychosis market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Postpartum Depression Drugs Market: Treatment Estimates & Trend Analysis

• 5.1. Global Postpartum Depression Drugs Market: Treatment Dashboard
• 5.2. Global Postpartum Depression Drugs Market: Treatment Movement Analysis
• 5.3. Global Postpartum Depression Drugs Market Estimates and Forecasts, By Treatment, Revenue (USD Million)
• 5.4. Pharmacotherapy
  • 5.4.1. Pharmacotherapy market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Hormonal Therapy
  • 5.5.1. Hormonal therapy market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Others
  • 5.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Postpartum Depression Drugs Market: Route of Administration Estimates & Trend Analysis

• 6.1. Global Postpartum Depression Drugs Market: Route of Administration Dashboard
• 6.2. Global Postpartum Depression Drugs Market: Route of Administration Movement Analysis
• 6.3. Global Postpartum Depression Drugs Market Estimates and Forecasts, by Route of Administration, Revenue (USD Million)
• 6.4. Parenteral
  • 6.4.1. Parenteral market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Oral
  • 6.5.1. Oral market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Others
  • 6.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Postpartum Depression Drugs Market: Distribution Channel Estimates & Trend Analysis

• 7.1. Global Postpartum Depression Drugs Market: Distribution Channel Dashboard
• 7.2. Global Postpartum Depression Drugs Market: Distribution Channel Movement Analysis
• 7.3. Global Postpartum Depression Drugs Market Estimates and Forecasts by Distribution Channel, Revenue (USD Million)
• 7.4. Hospital Pharmacy
  • 7.4.1. Hospital pharmacy market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Retail Pharmacy
  • 7.5.1. Retail pharmacy market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Others (Online Pharmacy)
  • 7.6.1. Others (online pharmacy) market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Postpartum Depression Drugs Market: Regional Estimates & Trend Analysis by Treatment, Therapeutic Class, and Route of Administration

• 8.1. Regional Dashboard
• 8.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 8.3. North America
  • 8.3.1. U.S.
    • 8.3.1.1. Key country dynamics
    • 8.3.1.2. Regulatory framework/ reimbursement structure
    • 8.3.1.3. Competitive scenario
    • 8.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.3.2. Canada
    • 8.3.2.1. Key country dynamics
    • 8.3.2.2. Regulatory framework/ reimbursement structure
    • 8.3.2.3. Competitive scenario
    • 8.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.3.3. Mexico
    • 8.3.3.1. Key country dynamics
    • 8.3.3.2. Regulatory framework/ reimbursement structure
    • 8.3.3.3. Competitive scenario
    • 8.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 8.4. Europe
  • 8.4.1. UK
    • 8.4.1.1. Key country dynamics
    • 8.4.1.2. Regulatory framework/ reimbursement structure
    • 8.4.1.3. Competitive scenario
    • 8.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.2. Germany
    • 8.4.2.1. Key country dynamics
    • 8.4.2.2. Regulatory framework/ reimbursement structure
    • 8.4.2.3. Competitive scenario
    • 8.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.3. France
    • 8.4.3.1. Key country dynamics
    • 8.4.3.2. Regulatory framework/ reimbursement structure
    • 8.4.3.3. Competitive scenario
    • 8.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.4. Italy
    • 8.4.4.1. Key country dynamics
    • 8.4.4.2. Regulatory framework/ reimbursement structure
    • 8.4.4.3. Competitive scenario
    • 8.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.5. Spain
    • 8.4.5.1. Key country dynamics
    • 8.4.5.2. Regulatory framework/ reimbursement structure
    • 8.4.5.3. Competitive scenario
    • 8.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.6. Norway
    • 8.4.6.1. Key country dynamics
    • 8.4.6.2. Regulatory framework/ reimbursement structure
    • 8.4.6.3. Competitive scenario
    • 8.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.7. Sweden
    • 8.4.7.1. Key country dynamics
    • 8.4.7.2. Regulatory framework/ reimbursement structure
    • 8.4.7.3. Competitive scenario
    • 8.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.8. Denmark
    • 8.4.8.1. Key country dynamics
    • 8.4.8.2. Regulatory framework/ reimbursement structure
    • 8.4.8.3. Competitive scenario
    • 8.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 8.5. Asia Pacific
  • 8.5.1. Japan
    • 8.5.1.1. Key country dynamics
    • 8.5.1.2. Regulatory framework/ reimbursement structure
    • 8.5.1.3. Competitive scenario
    • 8.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.2. China
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory framework/ reimbursement structure
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.3. India
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Regulatory framework/ reimbursement structure
    • 8.5.3.3. Competitive scenario
    • 8.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.4. Australia
    • 8.5.4.1. Key country dynamics
    • 8.5.4.2. Regulatory framework/ reimbursement structure
    • 8.5.4.3. Competitive scenario
    • 8.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.5. South Korea
    • 8.5.5.1. Key country dynamics
    • 8.5.5.2. Regulatory framework/ reimbursement structure
    • 8.5.5.3. Competitive scenario
    • 8.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.6. Thailand
    • 8.5.6.1. Key country dynamics
    • 8.5.6.2. Regulatory framework/ reimbursement structure
    • 8.5.6.3. Competitive scenario
    • 8.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 8.6. Latin America
  • 8.6.1. Brazil
    • 8.6.1.1. Key country dynamics
    • 8.6.1.2. Regulatory framework/ reimbursement structure
    • 8.6.1.3. Competitive scenario
    • 8.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.2. Argentina
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory framework/ reimbursement structure
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 8.7. MEA
  • 8.7.1. South Africa
    • 8.7.1.1. Key country dynamics
    • 8.7.1.2. Regulatory framework/ reimbursement structure
    • 8.7.1.3. Competitive scenario
    • 8.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.2. Saudi Arabia
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory framework/ reimbursement structure
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.3. UAE
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Regulatory framework/ reimbursement structure
    • 8.7.3.3. Competitive scenario
    • 8.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.4. Kuwait
    • 8.7.4.1. Key country dynamics
    • 8.7.4.2. Regulatory framework/ reimbursement structure
    • 8.7.4.3. Competitive scenario
    • 8.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Company/Competition Categorization
• 9.2. Vendor Landscape
  • 9.2.1. List of key distributors and channel partners
  • 9.2.2. Key customers
  • 9.2.3. Key company market share analysis, 2023
  • 9.2.4. Sage Therapeutics, Inc.
    • 9.2.4.1. Company overview
    • 9.2.4.2. Financial performance
    • 9.2.4.3. Product benchmarking
    • 9.2.4.4. Strategic initiatives
  • 9.2.5. Pfizer Inc.
    • 9.2.5.1. Company overview
    • 9.2.5.2. Financial performance
    • 9.2.5.3. Product benchmarking
    • 9.2.5.4. Strategic initiatives
  • 9.2.6. Eli Lilly and Company.
    • 9.2.6.1. Company overview
    • 9.2.6.2. Financial performance
    • 9.2.6.3. Product benchmarking
    • 9.2.6.4. Strategic initiatives
  • 9.2.7. GSK plc
    • 9.2.7.1. Company overview
    • 9.2.7.2. Financial performance
    • 9.2.7.3. Product benchmarking
    • 9.2.7.4. Strategic initiatives
  • 9.2.8. Merck & Co., Inc.
    • 9.2.8.1. Company overview
    • 9.2.8.2. Financial performance
    • 9.2.8.3. Product benchmarking
    • 9.2.8.4. Strategic initiatives
  • 9.2.9. Biogen Inc.
    • 9.2.9.1. Company overview
    • 9.2.9.2. Financial performance
    • 9.2.9.3. Product benchmarking
    • 9.2.9.4. Strategic initiatives
  • 9.2.10. Bausch Health Companies Inc.
    • 9.2.10.1. Company overview
    • 9.2.10.2. Financial performance
    • 9.2.10.3. Product benchmarking
    • 9.2.10.4. Strategic initiatives
  • 9.2.11. Cipla Inc.
    • 9.2.11.1. Company overview
    • 9.2.11.2. Financial performance
    • 9.2.11.3. Product benchmarking
    • 9.2.11.4. Strategic initiatives
  • 9.2.12. Novartis AG.
    • 9.2.12.1. Company overview
    • 9.2.12.2. Financial performance
    • 9.2.12.3. Product benchmarking
    • 9.2.12.4. Strategic initiatives
  • 9.2.13. Teva Pharmaceutical Industries Ltd.
    • 9.2.13.1. Company overview
    • 9.2.13.2. Financial performance
    • 9.2.13.3. Product benchmarking
    • 9.2.13.4. Strategic initiatives